Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC)

Texto completo
Autor(es):
Alves-Fernandes, Debora Kristina [1] ; de Oliveir, Erica Aparecida [1] ; Faiao-Flores, Fernanda [1, 2] ; Alicea-Rebecca, Gretchen [3] ; Weeraratna, Ashani T. [3] ; Smalley, Keiran S. M. [2] ; de Moraes Barros, Silvia Berlanga [1] ; Maria-Engler, Silvya Stuchi [1]
Número total de Autores: 8
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Skin Biol & Melanoma Lab, 580 Prof Lineu Prestes Ave, BR-05508000 Sao Paulo - Brazil
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL - USA
[3] Wistar Inst Anat & Biol, Melanoma Res Ctr, Immunol Microenvironm & Metastasis, 3601 Spruce St, Philadelphia, PA 19104 - USA
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: PHARMACOLOGICAL RESEARCH; v. 141, p. 63-72, MAR 2019.
Citações Web of Science: 1
Resumo

Melanoma accounts for only 4% of malignant neoplasms of the skin, but is considered the most serious because it is highly deadly. Mutations in the MAPK (Ras-Raf-MEK-ERK) pathway is closely linked to the lack of control of cell proliferation. Especially in melanoma, this pathway has become a target for the development of oncogene-targeted therapies, such as the potent inhibitors of v-Raf murine sarcoma viral oncogene homolog B (BRAFi) and mitogen-activated protein kinase kinase (MEKi). Very high rates of response have been achieved, but most patients are relapsed due to the development of resistance, justifying the constant search for new therapeutic compounds. Early results from our group indicated that 4-nerolidylcatechol (4-NC), a catechol compound extracted from Pothomorphe umbellata, induces DNA damage, ROS production, increased p53 expression culminating in apoptosis in melanoma but with no data regarding the 4-NC effects in cells resistant to BRAFi or MEKi. Therefore, here we evaluated the role of 4-NC alone or in combination with BRAFi/MEKi in resistant melanoma cells. Double-resistant cells were generated and characterized by MAPK pathway reactivation. 4-NC alone or in combination (30 mu M) with MAPK inhibitors was cytotoxic, inhibited colony formation and decreased invasiveness in two and three-dimensional cell culture models of treatment-naive, BRAFi-resistant and BRAF/MEKi double-resistant melanoma cells. Apoptosis induction was demonstrated in resistant and double-resistant melanoma cell lines after 4-NC treatments. 4-NC showed important ability to induce apoptosis via Endoplasmatic Reticulum (ER) stress and specifically BiP and CHOP that had increased protein expression in all melanoma cell lines proving to be part of the ER stress pathway activation. CHOP knockdown slightly but enough increases cellular viability following 4-NC treatment indicating that apoptosis observed is partially dependent on CHOP. In summary, we show that 4-NC is a compound with activity against cutaneous melanoma, including resistant cells to clinically approved therapies. (AU)

Processo FAPESP: 17/07010-2 - Efeitos das alterações relacionadas ao envelhecimento na angiogênese e linfangiogênese no microambiente tumoral
Beneficiário:Débora Kristina Alves Fernandes
Linha de fomento: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
Processo FAPESP: 14/24400-0 - Modelos in vitro para estudos pré-clínicos de melanoma quimioresistente
Beneficiário:Silvya Stuchi Maria-Engler
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 14/06959-0 - Avaliação do potencial de superação da quimioresistência do melanoma aos inibidores de BRAFV600E (vemurafenibe) e de MEK (trametinibe) utilizando terapia combinatória com 4-nerolidilcatecol (4-NC)
Beneficiário:Débora Kristina Alves Fernandes
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 17/04926-6 - Melanoma e quimioresistência: modelos in vitro e in silico para explorar alvos terapêuticos
Beneficiário:Silvya Stuchi Maria-Engler
Linha de fomento: Auxílio à Pesquisa - Temático